Diseases that are to be treated with a drug for which a PGx guideline has been published
Conditions
Interventions
Group 1: The observation period for the individual patient corresponds to the time of hospitalization. The follow-up for each patient is 3 years.
Sponsors
Robert Bosch Gesellschaft für medizinische Forschung mbH (RBMF)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Adults aged 18 or older • Ability to give independent informed consent • Signed written informed consent • actual or planned prescription of at least one of the concerned drugs
Exclusion criteria
Exclusion criteria: • Inability to give independent informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Within this project we will introduce pharmacogenetic testing to the daily hospital routine. A defined panel of different pharmacogenetic variants is included in the testing. The results of the pharmacogenetic testing will be linked to PGx guidelines (DPWAG, CPIC) providing dosing recommendations for the concerned drugs using the GIMS software. The resulting pharmacogenetic report will be made available for the attending physician. Important note: The therapy decision is the sole responsibility of the attending physician. | — |
Secondary
| Measure | Time frame |
|---|---|
| Investigation of the acceptance of pharmacogenetic testing and the occurence of adverse drug reactions despite dosing according to pharmacogenetic profile in the outpatient setting. | — |
Countries
Germany
Contacts
Public ContactMatthias Schwab
Dr. Margarete Fischer-Bosch - Institut für Klinische Pharmakologie
Outcome results
None listed